Back to top
more

Revvity, Inc. (RVTY)

(Delayed Data from NYSE)

$121.25 USD

121.25
578,499

+1.86 (1.56%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $121.19 -0.06 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (148 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Debanjana Dey headshot

Medical Device Stocks' Earnings on Feb 1: RVTY, CAH & More

by Debanjana Dey

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how CAH, RVTY, CNMD, SRDX and BDX are placed ahead of their earnings releases.

Revvity (RVTY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Revvity's (RVTY) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for its Life Sciences and Diagnostics franchises.

Revvity (RVTY) Launches New Molecular Testing for Newborns

by Zacks Equity Research

Revvity's (RVTY) EONIS Q System is set to transform SMA and SCID testing, advancing global healthcare for infants.

Company News for Oct 31, 2023

by Zacks Equity Research

Companies in The News Are: HLIT, JKS, RVTY, ON.

Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View

by Zacks Equity Research

Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.

Compared to Estimates, Revvity (RVTY) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Revvity (RVTY) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Revvity (RVTY) delivered earnings and revenue surprises of -0.84% and 3.10%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Revvity (RVTY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Revvity's (RVTY) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Bausch + Lomb (BLCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revvity's (RVTY) New Tie-Up to Boost NGS Research Workflow

by Zacks Equity Research

Revvity's (RVTY) latest partnership is likely to address the workflow-related challenges faced by labs and democratize genomic sequencing.

Revvity's (RVTY) New Launch to Widen Access to Editing Technology

by Zacks Equity Research

Revvity's (RVTY) latest offering is likely to improve access to new-generation editing technology and bridge both preclinical and clinical discoveries with the same technology platform.

Revvity (RVTY) Launches Three New Preclinical Research Systems

by Zacks Equity Research

Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity's prospect.

Revvity (RVTY) Down 4.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Revvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS View

by Zacks Equity Research

Revvity's (RVTY) second-quarter results reflect the impact of lower COVID-related sales. Both earnings and sales outpace their respective consensus estimate.

Compared to Estimates, Revvity (RVTY) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Revvity (RVTY) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Revvity (RVTY) delivered earnings and revenue surprises of 2.54% and 0.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Revvity's (RVTY) second-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

Earnings Preview: Revvity (RVTY) Q2 Earnings Expected to Decline

by Zacks Equity Research

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revvity (RVTY) Launches Single Solution for Drug Development

by Zacks Equity Research

Revvity (RVTY) Signals Software suite integrates streamlining data, global monitoring and customizable workflows and covers the entire Make-Test-Decide lifecycle, which can be centrally managed.

Revvity (RVTY) Launches New System for Autoimmune Diagnostics

by Zacks Equity Research

Revvity's (RVTY) EUROIMMUN launches UNIQO 160, a new automated system for autoimmune disease diagnostics using indirect immunofluorescence test.